The global market for anticancer monoclonal antibodies (MAbs) was valued at approximately USD $$ billion in 2022 and is projected to exhibit a robust growth rate of over $% during the forecast period ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss ...
NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agenttm. This advanced AI tool is a cornerstone of the company's ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback